Incidence and Prevalence of Microvascular and Macrovascular Diseases and All-cause Mortality in Type 2 Diabetes Mellitus: A 10-year Study in a US Commercially Insured and Medicare Advantage Population
- PMID: 31196656
- DOI: 10.1016/j.clinthera.2019.05.012
Incidence and Prevalence of Microvascular and Macrovascular Diseases and All-cause Mortality in Type 2 Diabetes Mellitus: A 10-year Study in a US Commercially Insured and Medicare Advantage Population
Abstract
Purpose: The relationship between type 2 diabetes mellitus (T2DM) and increased microvascular and macrovascular disease and mortality is well established; however, data for the broad US T2DM population, especially by age, are limited. To help address this issue, we conducted a cohort study in a large national US commercially insured/Medicare Advantage population that incorporated a broad range of different age groups, including a large subset of younger individuals, during a 10-year study period.
Methods: This longitudinal study combined health plan claims and mortality data to identify incident T2DM patients and 1:1 directly matched non-DM controls. T2DM individuals (n = 13,883) were identified by a medical claim with a T2DM diagnosis or T2DM medication pharmacy claim in 2007; non-DM controls had no DM medical or pharmacy claims over the entire study period (January 1, 2006 to December 31, 2015). The outcomes assessed were incidence, prevalence, time to vascular disease and all-cause mortality, as well as age-stratified incidence and mortality based on Centers of Disease Control and Prevention-defined age strata.
Findings: Individuals with T2DM developed vascular disease at twice the rate as non-DM controls, 197 versus 98 per 1000 person-years, respectively. Vascular disease (composite) rates increased by age in T2DM/non-DM groups, 107.1/28.2 (18-44 years), 166.3/70.3 (45-64 years), and 391.0/199.7 (≥65 years) per 1000 person-years. The largest rate ratio was observed in younger individuals. All-cause mortality over follow-up was higher in T2DM individuals (27.5%) than in non-DM controls (19.6%). The largest increases in vascular disease prevalence and mortality among T2DM individuals were observed in the first year of follow-up.
Implications: T2DM has a substantial effect on microvascular and macrovascular disease and all-cause mortality rates in all age groups. These outcomes appear to occur early after T2DM diagnosis, and have more pronounced, nearly fourfold, relative impact on younger individuals with T2DM compared to matched non-DM controls.
Keywords: complications; macrovascular disease; microvascular disease; prevalence; time to first disease type 2 diabetes mellitus.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.J Manag Care Pharm. 2006 Sep;12(7):546-54. doi: 10.18553/jmcp.2006.12.7.546. J Manag Care Pharm. 2006. PMID: 16981800 Free PMC article.
-
Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study.Clinicoecon Outcomes Res. 2020 Aug 10;12:423-434. doi: 10.2147/CEOR.S247498. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32848433 Free PMC article.
-
Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.Curr Med Res Opin. 2010 Aug;26(8):1827-34. doi: 10.1185/03007995.2010.488544. Curr Med Res Opin. 2010. PMID: 20491613
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Young-onset type 2 diabetes mellitus - implications for morbidity and mortality.Nat Rev Endocrinol. 2020 Jun;16(6):321-331. doi: 10.1038/s41574-020-0334-z. Epub 2020 Mar 20. Nat Rev Endocrinol. 2020. PMID: 32203408 Review.
Cited by
-
Arginase Gene Polymorphism Increases Risk of Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients.J Clin Med. 2021 Nov 19;10(22):5407. doi: 10.3390/jcm10225407. J Clin Med. 2021. PMID: 34830689 Free PMC article.
-
TSH levels within the normal range and risk of cardiovascular and all-cause mortality among individuals with diabetes.Cardiovasc Diabetol. 2022 Nov 23;21(1):254. doi: 10.1186/s12933-022-01698-z. Cardiovasc Diabetol. 2022. PMID: 36419168 Free PMC article.
-
Association of KCNJ11 E23K/rs5219 Gene Polymorphism with Type 2 Diabetes and Diabetes-Related Cardiovascular Disease.Diabetes Metab Syndr Obes. 2025 Feb 27;18:653-661. doi: 10.2147/DMSO.S506639. eCollection 2025. Diabetes Metab Syndr Obes. 2025. PMID: 40034481 Free PMC article.
-
Youth-onset type 2 diabetes mellitus: an urgent challenge.Nat Rev Nephrol. 2023 Mar;19(3):168-184. doi: 10.1038/s41581-022-00645-1. Epub 2022 Oct 31. Nat Rev Nephrol. 2023. PMID: 36316388 Free PMC article. Review.
-
Lifestyles Under Lockdown: A Scoping Review of International Studies on Type 2 Diabetes Self-Management Behaviors During COVID-19.Front Clin Diabetes Healthc. 2022 Mar 15;3:830353. doi: 10.3389/fcdhc.2022.830353. eCollection 2022. Front Clin Diabetes Healthc. 2022. PMID: 36992763 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical